Slide 1: Evotec to acquire Just Biotherapeutics
Evotec to acquire Just Biotherapeutics Multimodality becomes reality Evotec SE, Investor and Analyst call, 21 May 2019
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. We caution investors that forward-looking statements contained herein are based upon management’s expectations and assumptions as of the date o
Slide 3: Agenda
Agenda Strategic rationale and transaction overview Introduction to Just.Bio and the combined business Next steps PAGE 2
Slide 4: Just right for Evotec: Summary & Key acquisition rationale
Just right for Evotec Summary & Key acquisition rationale Modality expansion for end-to-end integrated solutions with Just.Bio ML (Machine learning) based tools, smart processes and know-how enable efficient development and manufacturing of biologics Integrated value chain from discovery to mark
Slide 5: More biologics will hit the marketplace
More biologics will hit the marketplace FDA approvals 2016–2018 Biologics Small molecule 59 17 46 12 22 42 7 34 15 2016 2017 2018 PAGE 4 Sources: Research and Markets, https://www.biopharmatrend.com/post/67-will-small-molecules-sustain-pharmaceutical-race-with-biologics/
Slide 6: Expanding our market reach significantly
Expanding our market reach significantly Small molecules, biologics & other modalities in R&D Global pharmaceutical market1), 2) US$ bn CAGR 2017-22e +7% 918 856 >50% 794 743 670 703 Cell/Gene therapy Biologics Small molecules 2017 2018e 2019e 2020e 2021e 2022e PAGE 5 1) Small molecules forecast fro
Slide 7: More flexibility for better defined patient populations
More flexibility for better defined patient populations Changes in marketplace Biologics global expected sales Avg. peak sales (SM & Biologics) The Opportunity in $ bn in $ m Biologics market is large, growing and ~500 800 open for technology improvements -42% High number of smaller volume pro-
Slide 8: Multi-modality "Autobahn" becomes reality
Multi-modality „Autobahn“ becomes reality Evotec‘s end-to-end integrated offering PAGE 7
Slide 9: With Just.Bio – Even more integrated offering
With Just.Bio – Even more integrated offering Comprehensive service panel for external innovation PAGE 8
Slide 10: Building a co-owned portfolio across all modalities
Building a co-owned portfolio across all modalities Unique strategy and business approach Own R&D Co-Owned Pipeline Action Plan 2022 Fee for Service PAGE 9
Slide 11: Agenda
Agenda Strategic rationale and transaction overview Introduction to Just.Bio and the combined business Next steps PAGE 10
Slide 12: Dramatically improved access to biologics
Dramatically improved access to biologics Just.Bio – Mission “Just believes that no matter where you live or what your income, every person should have access to life changing medicines.” James Thomas, PhD, Founder of Just.Bio, Inc. Quality Speed Capacity Cost PAGE 11 1) Note: At closing of the tran
Slide 13: Next stage biologics with truly efficient technologies
Next stage biologics with truly efficient technologies Overview – Just.Bio (www.justbiotherapeutics.com) Founded 2014/15, Private, based in Seattle, WA (USA) Approx. 90 employees Key Investors: ARCH Venture Partners, Merck & Co., Lilly Asia Ventures, Bill & Melinda Gates Foundation and employe
Slide 14: Better biologics by top experienced professionals
Better biologics by top experienced professionals It is about the people >1,000 years of collective experience in development of biologics PAGE 13
Slide 15: Building better molecules with better technologies
Building better molecules with better technologies J.DESIGN Technology Platform Molecular J.MD™ – Optimising molecules Design Using machine learning to design and J.MD™ select better biologics through molecular understanding and prediction with Abacus™, an ML software analysis tool JP3® – Optimi
Slide 16: Design and develop your molecule as you require
Design and develop your molecule as you require J.DESIGN (J.MD and JP3) J.MD™ – Optimizing Molecules: Building biologics for JP3® – Optimizing Processes: Tools for rapid devel- manufacturing & formulation opment of high yielding manufacturing processes Abacus™: ML – Machine Learning to drive molecul
Slide 17: Manufacture at highest efficiency – J.POD
Manufacture at highest efficiency – J.POD® J.DESIGN (J.POD®)1) J.POD® – Flexibility: The primary characteristic of next-generation biologics manufacturing, shifting costs from fixed to variable Flexible capacity for all modalities Seamless transfer from pilot plant to J.POD® PAGE 16 1) J.POD are cur
Slide 18: A powerful platform for biologics value chain
A powerful platform for biologics value chain World-class services for biologics development: J.MD™, JP3®, and J.POD® Target Hit- Lead Pre- Academia ID/Vali- Identi- Optimi- Phase I Phase II Phase III Approval Market clinical dation fication sation Molecule Optimisation – J.MD™ Process development –
Slide 19: Agenda
Agenda Strategic rationale and transaction overview Introduction to Just.Bio and combined business Next steps PAGE 18
Slide 20: Adding Seattle, to become a top biologics hotspot
Adding Seattle, to become a top biologics hotspot Global centres of excellence Abingdon, Alderley Park ~680 employees 1st J.POD Plant Hamburg, Göttingen, Munich ~610 employees Verona, Basel Branford, Princeton, Seattle, Toulouse, Lyon ~660 employees Watertown ~140 + approx. 90 ~550 employees employe
Slide 21: Transaction expected to become effective Q2 2019
Transaction expected to become effective Q2 2019 Summary of acquisition Purchase of all of Just.Bio’s shares with up to $ 90 m in cash, including Transaction potential earn outs upon defined milestones expected in 2019 – 2022e Transaction subject to customary conditions expected to close in June
Slide 22: HRESEARCHNEVE
HRESEARCHNEVE ASTOPS
Slide 23: Your contact: Dr Werner Lanthaler
Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax werner.lanthaler@evotec.com